HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 3 (2006), Issue 2 (February)

1. Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa.
   JAMA, 295(5): 519-26. [Abstract] [Full-text]
2. Nucleic acid binding and chaperone properties of HIV-1 Gag and nucleocapsid proteins.
   Nucleic Acids Res, 34(2): 593-605. [Abstract] [Full-text]
3. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study.
   Int J Cancer, 118(4): 985-90. [Abstract] [Full-text]
4. Reducing the risk of HIV infection associated with illicit drug use.
   Pediatrics, 117(2): 566-71. [Abstract] [Full-text]
5. Quality of life for children and adolescents: impact of HIV infection and antiretroviral treatment.
   Pediatrics, 117(2): 273-83. [Abstract] [Full-text]
6. Effect of maternal multivitamin supplementation on the mental and psychomotor development of children who are born to HIV-1-infected mothers in Tanzania.
   Pediatrics, 117(2): e216-25. [Abstract] [Full-text]
7. HIV decline associated with behavior change in eastern Zimbabwe.
   Science, 311(5761): 664-6. [Abstract] [Full-text]
8. Resolving the motional modes that code for RNA adaptation.
   Science, 311(5761): 653-6. [Abstract] [Full-text]
9. Ocular manifestation of cat-scratch disease in HIV-positive patients.
   Am J Ophthalmol, 141(2): 400-1. [Abstract] [Full-text]
10. Inhibition of HIV-1 virus replication using small soluble Tat peptides.
    Virology, 345(2): 373-89. [Abstract] [Full-text]
11. Construction and characterization of an infectious molecular clone of HIV-1 subtype A of Indian origin.
    Virology, 345(2): 328-36. [Abstract] [Full-text]
12. During the early phase of HIV-1 DNA synthesis, nucleocapsid protein directs hybridization of the TAR complementary sequences via the ends of their double-stranded stem.
    J Mol Biol, 356(5): 1180-92. [Abstract] [Full-text]
13. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes.
    Gut, 55(3): 409-14. [Abstract] [Full-text]
14. The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine.
    J Virol, 80(5): 2578-81. [Abstract] [Full-text]
15. Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.
    J Virol, 80(5): 2539-47. [Abstract] [Full-text]
16. Natural killer cell function is well preserved in asymptomatic human immunodeficiency virus type 2 (HIV-2) infection but similar to that of HIV-1 infection when CD4 T-cell counts fall.
    J Virol, 80(5): 2529-38. [Abstract] [Full-text]
17. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.
    J Virol, 80(5): 2515-28. [Abstract] [Full-text]
18. Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients.
    J Virol, 80(5): 2472-82. [Abstract] [Full-text]
19. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.
    J Virol, 80(5): 2463-71. [Abstract] [Full-text]
20. Ataxia-telangiectasia-mutated (ATM) protein can enhance human immunodeficiency virus type 1 replication by stimulating Rev function.
    J Virol, 80(5): 2445-52. [Abstract] [Full-text]
21. A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41.
    J Virol, 80(5): 2405-17. [Abstract] [Full-text]
22. Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay.
    J Virol, 80(5): 2380-9. [Abstract] [Full-text]
23. Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.
    J Virol, 80(5): 2092-9. [Abstract] [Full-text]
24. Basic residues in the nucleocapsid domain of Gag are required for interaction of HIV-1 gag with ABCE1 (HP68), a cellular protein important for HIV-1 capsid assembly.
    J Biol Chem, 281(7): 3773-84. [Abstract] [Full-text]
25. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits.
    Vaccine, 24(8): 1225-34. [Abstract] [Full-text]
26. HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity.
    Neurosci Lett, 395(3): 235-9. [Abstract] [Full-text]
27. CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site.
    J Gen Virol, 87: 607-12. [Abstract] [Full-text]
28. Role of myristoylation and N-terminal basic residues in membrane association of the human immunodeficiency virus type 1 Nef protein.
    J Gen Virol, 87: 563-71. [Abstract] [Full-text]
29. Insights on HIV-1 Tat:P/CAF bromodomain molecular recognition from in vivo experiments and molecular dynamics simulations.
    Proteins, 62(4): 1062-73. [Abstract] [Full-text]
30. Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers.
    Clin Exp Immunol, 143(3): 435-44. [Abstract] [Full-text]
31. CD127 expression and regulation are altered in the memory CD8 T cells of HIV-infected patients--reversal by highly active anti-retroviral therapy (HAART).
    Clin Exp Immunol, 143(3): 398-403. [Abstract] [Full-text]
32. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy.
    Am J Epidemiol, 163(5): 412-20. [Abstract] [Full-text]
33. Cellular immune response to pulmonary infections in HIV-infected individuals hospitalized with diverse grades of immunosuppression.
    Epidemiol Infect, 134(2): 271-8. [Abstract] [Full-text]
34. Molecular epidemiology of long-term colonization of Candida albicans strains from HIV-infected patients.
    Epidemiol Infect, 134(2): 265-9. [Abstract] [Full-text]
35. The rational design of an AIDS vaccine.
    Cell, 124(4): 677-81. [Abstract] [Full-text]
36. Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage.
    Bull World Health Organ, 84(2): 145-50. [Abstract] [Full-text]
37. Hybrid data capture for monitoring patients on highly active antiretroviral therapy (HAART) in urban Botswana.
    Bull World Health Organ, 84(2): 127-31. [Abstract] [Full-text]
38. Effect of the HIV epidemic on infant feeding in South Africa: "When they see me coming with the tins they laugh at me".
    Bull World Health Organ, 84(2): 90-6. [Abstract] [Full-text]
39. Desperately seeking targets: the ethics of routine HIV testing in low-income countries.
    Bull World Health Organ, 84(1): 52-7. [Abstract] [Full-text]
40. Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.
    Expert Rev Anticancer Ther, 6(3): 335-41. [Abstract] [Full-text]
41. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.
    Expert Opin Drug Saf, 5(2): 275-87. [Abstract] [Full-text]
42. Oral bowenoid papulosis in an HIV-positive male.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 101(3): 328-32. [Abstract] [Full-text]
43. Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy.
    Stroke, 37(3): 812-7. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.